An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Active, not recruiting · NCT02648997 · Registry updated 2026-07-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, central nervous system cancer, meningioma, neoplasm, nervous system disorder, tumor of meninges, vascular cancer | Active, not recruiting | Phase 2 | 2026-07-10 | NCT02648997 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Dana-Farber Cancer Institute | 324 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 68 |